NCT07076680

A Real-World Study in Patients With HR+/HER2- Advanced Breast Cancer

Safety and Effectiveness in Patients With HR+/HER2- Advanced Breast Cancer: a Prospective, Noninterventional Real-world Study

• Status: Withdrawn
• Phase: —
• Study type: Observational
• Enrollment: 0 (actual)
• Sponsor: SciClone Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this observational study is to learn about the safety and effectiveness of people with advanced breast cancer that is hormone receptor-positive (HR+), HER2-negative (HER2-). Participants will: Allow researchers to collect medical data during routine care Be followed for signs of treatment effectiveness and any medical problems that happen while taking the drug

Conditions

• Breast Cancer Metastatic
• HR+/HER2- Advanced Breast Cancer

Timeline

• Start date: 2025-08-01
• Primary completion: 2027-02-01
• Completion: 2027-07-01
• First posted: 2025-07-22
• Last updated: 2025-11-28

Locations

1 site across 1 country: China